Hepatocellular carcinoma is one leading cause of cancer-related death and surgical resection is still one of the major curative therapies. Recently, there has been a major effort to find mechanisms involved in carcinogenesis and early relapse. c-myc gene abnormality is found in hepatocarcinogenesis. Our aim was to analyze the role of c-myc as prognostic factor in terms of overall survival and disease-free survival and to investigate if c-myc may be an important target for therapy. We studied sixty-five hepatocellular carcinomas submitted to surgical resection with curative intent. Size, macro-microvascular invasion, necrosis, number of nodules, grading and serum alfa-fetoprotein level were registered for all cases. We evaluated the c-myc aberrations by using break-apart FISH probes. Probes specific for the centromeric part of chromosome 8 and for the locus specific c-myc gene (8q24) were used to assess disomy, gains of chromosomes (polysomy due to polyploidy) and amplification. c-myc gene amplification was scored as 8q24/CEP8 > 2. Statistical analysis for disease-free survival and overall survival were performed. At molecular level, c-myc was amplified in 19% of hepatocellular carcinoma, whereas showed gains in 55% and set wild in 26% of cases. The 1- and 3-year disease-free survival and overall survival for disomic, polysomic and amplified groups were significantly different (p=0.020 and p=.018 respectively). Multivariate analysis verified that the AFP and c-myc status (amplified vs. not amplified) were significant prognostic factors for overall patients survival. c-myc gene amplification is significantly correlated with disease-free survival and overall survival in patients with hepatocellular carcinoma after surgical resection and this model identifies patients with risk of early relapse (≤12 months). We suggest that c-myc assessment may be introduced in the clinical practice for improving prognostication (high and low risk of relapse) routinely and may have be proposed as biomarker of efficacy to anti-c-myc targeted drugs in clinical trials.
References
[1]
Venook AP, Papandreou C, Furuse J, de Guevara LL (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 Suppl 4: 5-13. doi:10.1634/theoncologist.2010-S1-5. PubMed: 21115576.
[2]
Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR et al. (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141: 330-339. doi:10.1016/j.surg.2006.06.028. PubMed: 17349844.
[3]
Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200. doi:10.1055/s-2005-871198. PubMed: 15918147.
[4]
Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S et al. (2002) Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 131: S148-S152. doi:10.1067/msy.2002.119496. PubMed: 11821802.
[5]
Poon RT, Fan ST, Lo CM, Liu CL, Wong J (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229: 216-222. doi:10.1097/00000658-199902000-00009. PubMed: 10024103.
[6]
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207. doi:10.1016/S0270-9139(03)80135-0. PubMed: 12547409.
[7]
Villanueva A, Minguez B, Forner A, Reig M, Llovet JM (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317-328. doi:10.1146/annurev.med.080608.100623. PubMed: 20059340.
[8]
Zhang QL, Luo CL, Wu XH, Wang CY, Xu X et al. (2011) HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem 112: 2910-2919. doi:10.1002/jcb.23207. PubMed: 21618595.
[9]
Tang SW, Chang WH, Su YC, Chen YC, Lai YH et al. (2009) MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 273: 35-43. doi:10.1016/j.canlet.2008.07.038. PubMed: 18809243.
[10]
Cuadros M, Villegas R (2009) Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 17: 1-7. doi:10.1097/PAI.0b013e318169fc1c. PubMed: 18685491.
[11]
Albarello L, Pecciarini L, Doglioni C (2011) HER2 testing in gastric cancer. Adv Anat Pathol 18: 53-59. doi:10.1097/PAP.0b013e3182026d72. PubMed: 21169738.
[12]
Camidge DR, Theodoro M, Maxson DA, Skokan M, O’Brien T et al. (2012) Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 118: 4486-4494. doi:10.1002/cncr.27411. PubMed: 22282074.
[13]
Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N et al. (2009) Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neuro Oncol 91: 33-38. doi:10.1007/s11060-008-9690-6. PubMed: 18781279.
[14]
Dang CV, Le A, Gao P (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483. doi:10.1158/1078-0432.CCR-09-0889. PubMed: 19861459.
[15]
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917. doi:10.1016/j.cell.2011.08.017. PubMed: 21889194.
[16]
Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM et al. (2002) Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 26: 25-34. doi:10.1097/00000478-200201000-00003. PubMed: 11756766.
[17]
Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503. doi:10.1002/1097-0142(195405)7:3. PubMed: 13160935.
[18]
Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A et al. (2008) HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 129: 907-911. doi:10.1309/MD79CDXN1D01E862. PubMed: 18480007.
[19]
Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C et al. (2007) Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 14: 2337-2347. doi:10.1245/s10434-007-9415-7. PubMed: 17503155.
[20]
Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC et al. (2012) Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg 36: 151-156. doi:10.1007/s00268-011-1323-0. PubMed: 22030561.
[21]
Poon RT, Fan ST, Ng IO, Wong J (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 231: 544-551. doi:10.1097/00000658-200004000-00014. PubMed: 10749616.
[22]
Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P et al. (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779-6788. doi:10.1158/0008-5472.CAN-08-0742. PubMed: 18701503.
[23]
Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52. doi:10.1002/hep.21467. PubMed: 17187432.
[24]
Villanueva A, Hoshida Y, Llovet JM (2011) Hepatocellular carcinoma enters the sequencing era. Gastroenterology 141: 1943-1945. doi:10.1053/j.gastro.2011.09.027. PubMed: 21963842.
[25]
Yamashita T, Forgues M, Wang W, Kim JW, Ye Q et al. (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461. doi:10.1158/0008-5472.CAN-07-6013. PubMed: 18316609.
[26]
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004. doi:10.1056/NEJMoa0804525. PubMed: 18923165.
[27]
Chan KL, Guan XY, Ng IO (2004) High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 35: 1324-1331. doi:10.1016/j.humpath.2004.06.012. PubMed: 15668888.
[28]
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392. doi:10.1158/0008-5472.CAN-09-1089. PubMed: 19723656.
[29]
Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y (1999) Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57: 157-163. doi:10.1159/000012024. PubMed: 10461064.
[30]
Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ et al. (2002) Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95: 2346-2352. doi:10.1002/cncr.10963. PubMed: 12436441.
[31]
Kuo SH, Sheu JC, Chen DS, Sung JL, Lin CC et al. (1987) DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by Feulgen-DNA analysis. Liver 7: 359-363. PubMed: 2830450.
[32]
Hui AM, Kawasaki S, Imamura H, Miyagawa S, Ishii K et al. (1997) Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas. Br J Cancer 76: 335-339. doi:10.1038/bjc.1997.387. PubMed: 9252200.
[33]
Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S, Davidson BR, Dhillon AP et al. (1999) Genomic heterogeneity in synchronous hepatocellular carcinomas. Gut 45: 761-765. doi:10.1136/gut.45.5.761. PubMed: 10517917.
[34]
Nakata T, Seki N, Miwa S, Kobayashi A, Soeda J et al. (2008) Identification of genes associated with multiple nodules in hepatocellular carcinoma using cDNA microarray: multicentric occurrence or intrahepatic metastasis? Hepatogastroenterology 55: 865-872. PubMed: 18705285.
[35]
Saeki R, Nagai H, Kaneko S, Unoura M, Yamanaka N et al. (2000) Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol 33: 99-105. doi:10.1016/S0168-8278(00)80165-8. PubMed: 10905592.
[36]
Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716. doi:10.1002/hep.20636. PubMed: 15795889.
[37]
Marelli L, Grasso A, Pleguezuelo M, Martines H, Stigliano R et al. (2008) Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol 15: 3503-3511. doi:10.1245/s10434-008-0128-3. PubMed: 18777193.
Zhao WC, Zhang HB, Yang N, Fu Y, Qian W et al. (2012) Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol 18: 3272-3281. PubMed: 22783052.
[40]
Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D et al. (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140: 1501-1512 e1502. doi:10.1053/j.gastro.2011.02.006. . PubMed : 21320499.
[41]
Zhang Y, Wei W, Cheng N, Wang K, Li B et al. (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56: 1631-1640. doi:10.1002/hep.25849. PubMed: 22610915.
[42]
Liu J, Ding X, Tang J, Cao Y, Hu P et al. (2011) Enhancement of canonical Wnt/beta-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLOS ONE 6: e27496. doi:10.1371/journal.pone.0027496. PubMed: 22110662.
[43]
Li W, Miao X, Qi Z, Zeng W, Liang J et al. (2010) Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. Virol J 7: 45. doi:10.1186/1743-422X-7-45. PubMed: 20170530.
[44]
Kluin P, Schuuring E (2011) Molecular cytogenetics of lymphoma: where do we stand in 2010? Histopathology 58: 128-144. doi:10.1111/j.1365-2559.2010.03700.x. PubMed: 21261688.
